Akari Therapeutics Plc has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-28 · Confirms AKTX ticker, listed issuer name, exchange and CIK where available.SEC APISEC submissions for Akari Therapeutics PlcRetrieved 2026-05-28 · Company identity, filing chronology, fiscal year end, SIC description, addresses and latest filing metadata.SEC XBRL APISEC companyfacts for Akari Therapeutics PlcRetrieved 2026-05-28 · XBRL-derived revenue, profit, cash-flow and balance-sheet cross-checks when tagged facts are available.10-KAkari Therapeutics Plc annual report2026-03-30 · annual report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.10-QAkari Therapeutics Plc latest quarterly or interim report2026-05-19 · latest quarterly or interim report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.8-KAkari Therapeutics Plc current report2026-05-22 · current report. Used for business description, risk factors, financial statement context, governance chronology or recent event review.DEF 14AAkari Therapeutics Plc proxy statement2026-02-02 · proxy statement. Used for business description, risk factors, financial statement context, governance chronology or recent event review.